Intramuscular stimulation lead with enhanced infection resistance

• US 5,834,051 A
• Filed: 02/19/1997
• Issued: 11/10/1998
• Est. Priority Date: 11/07/1995
• Status: Expired due to Term

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Hendriks, Marc, Cahalan, Patrick T., Verhoeven, Michel L. P. M., Cahalan, Linda L., Camps, Antoine N. J., Woloszko, Jean A.
• Primary Examiner(s): DUDASH, DIANA L
• Application Number:
  US08/801,986
• Time in Patent Office: 629 Days
• Field of Search: 427/2.12, 427/2.13, 427/2.24, 427/409, 427/412.1, 427/2.1
• US Class Current: 427/2.24
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence

Abstract

To minimize the incidence and consequences of device related infection that occur after prosthetics implants of neuro-muscular stimulating devices, an infection resistant intra-muscular lead has been developed and is disclosed herein. Infection incidence has been decreased by using biomaterials able to release antibacterial drugs (gentamicin) at a controlled rate for the first 3-6 weeks after implant.

Claims

1. In a method for making an implantable infection resistant medical electrical lead having a polymeric lead insulator, the insulator providing a cavity with an interior surface surrounding the lead, the improvement comprising:

providing a graft copolymer on the interior surface of the insulator;

coupling a bioactive agent to the graft copolymer by contacting the graft copolymer on the interior surface with the bioactive agent; and

sealing the cavity of the insulator to prevent free movement of body fluid into the cavity.

2. The method of claim 1 wherein the bioactive agent is releasably coupled to the graft copolymer.

3. The method of claim 1 wherein the bioactive agent is an antimicrobial agent.

4. The method of claim 1 wherein the lead insulator has an exterior surface, the improvement further comprising:

providing a graft copolymer on the exterior surface of the insulator; and

coupling a bioactive agent to the graft copolymer by contacting the graft copolymer on the exterior surface with the bioactive agent.

5. The method of claim 1 wherein the interior surface is polyurethane.

6. The method of claim 1 wherein the bioactive agent is covalently coupled to the graft copolymer.

7. The method of claim 1 wherein the graft copolymer is provided by polymerizing at least two vinyl functional monomers.

8. The method of claim 7 wherein the vinyl functional monomers comprise acrylamide monomer and a second monomer which has a positive or negative electrical charge.

9. The method of claim 8 wherein the second monomer is acrylic acid.

10. The method of claim 9 wherein acrylic acid is 50-75% of the graft copolymer.

11. The method of claim 10 wherein the bioactive agent is gentamicin.

12. The method of claim 10 wherein acrylic acid is 65-75% of the graft copolymer.

13. The method of claim 12 wherein the bioactive agent is gentamicin.

14. The method of claim 1 wherein coupling is conducted at a pH in the range of about pH 6 to pH 8.

15. The method of claim 2 wherein the graft copolymer provides a charge density on the interior surface, and wherein the bioactive agent is ionically coupled to the graft copolymer.

16. The method of claim 3 wherein the antimicrobial agent is an antibiotic.

17. The method of claim 9 further comprising, prior to providing the graft copolymer on the interior surface of the insulator, a step of determining a ratio of acrylamide to acrylic acid effective to cause sustained release of the bioactive agent from the graft copolymer upon contact with a physiological fluid, the release of the bioactive agent being essentially complete within a predetermined period, and wherein the graft copolymer provided on the interior surface of the insulator comprises acrylamide and acrylic acid in accordance with said ratio.

18. In a method for making an infection-resistant article having at least one biocompatible surface adapted for use in contact with the body or body constituents, blood or blood products the improvement comprising:

providing a graft copolymer of acrylamide and acrylic acid on the biocompatible surface such that the graft copolymer comprises 50% to 75% acrylic acid; and

ionically coupling a positively charged antimicrobial agent to the graft copolymer by contacting the graft copolymer on the surface with the antimicrobial agent.

19. The method of claim 18 wherein the graft copolymer comprises 65-75% acrylic acid.

20. The method of claim 18 wherein the biocompatible surface is a polymeric surface.

21. The method of claim 18 wherein the biocompatible surface is a metallic surface.

23. The method of claim 21 wherein release of the bioactive agent from the graft copolymer is essentially complete at the end of the predetermined period following implantation of the article.

24. The method of claim 21 wherein the predetermined period is about 3-6 weeks.

22. A method for making an infection-resistant article having at least one biocompatible surface adapted for use in contact with the body or body constituents, blood or blood products comprising:

providing a graft copolymer on the biocompatible surface of the article; and

ionically coupling a positively charged antimicrobial agent to the graft copolymer by contacting the graft copolymer on the biocompatible surface with the antimicrobial agent;

wherein the graft copolymer comprises acrylamide and acrylic acid in a ratio effective to cause sustained release of the bioactive agent from the graft copolymer during a predetermined period following implantation of the article in a body.

25. The method of claim 22 wherein the biocompatible surface is a polymeric surface.

26. The method of claim 22 wherein the biocompatible surface is a metallic surface.